Vandetanib and Cabozantinib Deemed Effective in Real-World Study of Medullary Thyroid Cancer
The overall survival rate at 1 year was 86% with vandetanib and 70% with cabozantinib.
Endocrine Cancer
Local Resection Is ‘Sufficient’ for Parathyroid Carcinoma
Patients with parathyroid carcinoma after localized resection for a presumed benign indication should undergo close monitoring for recurrence rather than radical surgery.
Lenvatinib Produces ‘Strong’ Responses in Resistant Gastroenteropancreatic Neuroendocrine Tumors
The response rate was higher for patients with pancreatic NETs than for those with gastrointestinal NETs.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Lenvatinib Monotherapy Produces Low Response Rate in Anaplastic Thyroid Cancer
In a phase 2 trial, lenvatinib produced an objective response rate of about 3%.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Cabozantinib Improved PFS, May Be New Standard for Radioiodine-Refractory Thyroid Cancer
Cabozantinib significantly improved progression-free survival, and there was a trend toward improved overall survival.
Mutational Risk Not Associated With Distant Metastasis in Medullary Thyroid Cancer
Researchers identified risk factors for distant metastasis in sporadic and hereditary medullary thyroid cancer.
- Loading...
Loading...
Next post in Endocrine Cancer
Loading... 
Loading...